Chat with MASH AI
Hi, I am MASH AI.
Suggested Questions :
MASH AI 12:40 PM
At January 23, 2025
-
Gabriella McCarty
-
Alison Moe
-
Christie Morrison
-
Jill Olmstead
-
Oyin Penny
-
Emily Przybyl
-
Lisa Richards
-
Sharon Rimon
-
Jordan Mayberry
-
Carla Molliner
-
Anne Moore
-
April Morris
-
Janet Gripshover
-
Milly Ng
-
Michelle Barnett
-
Erin Parkinson
-
Christina Hanson
-
Summer Collier
-
Allysa Saggese
-
Patrick Horne
-
Valerie Shin
-
Lavina Lordache
-
Elizabeth Simkus
-
Tessa Janovsky
-
Kelly Smeester
-
Jeremy Davis
-
Chantil Jefferys
-
Robin Soto
-
Edith Johannes
-
Becky Klemme
-
Brian Lam
-
Scott Springer
-
Viet Le
-
Whitney Steinmetz
-
Sarah Dawkins
-
Erin Tanner
-
Maly Tiev
-
Jonathan Yeh
-
Lindsay Yoder
-
Anthony Derencius
-
Melissa Franco
-
Jennifer Geremia
-
HoChong Gilles
-
Elizabeth Goacher
-
Ellie Gonyeau
-
Andrea Gossard
-
Jessica Crimaldi
-
Maribeth Capuno
-
Lindsay Pratt
-
Amy Rourke
-
Elizabeth Alqueza
Explore advancements in non-invasive diagnostics and risk stratification for liver fibrosis and MASH. This video highlights tools like FIB-4, transient elastography, and innovative scoring systems (e.g., FAST and Agile) to identify and predict outcomes for high-risk patients. Learn about serum biomarkers, updated guidelines, and the role of lifestyle interventions alongside targeted therapies for managing metabolic risks and advancing care in hepatology.
Related Video
Approved Medication for MASH/NASH
At Jan 23, 2025
This video provides detailed guidance on selecting and monitoring patients for emerging therapies targeting advanced fibrosis (F2-F3) in NASH. Key topics include contraindications for patients with cirrhosis, considerations for concomitant medications, and dose adjustments for statins. The video outlines ideal candidates based on specific thresholds for VCTE, MRE, ELF scores, and other non-invasive tests while emphasizing the importance of ruling out portal hypertension and other liver diseases. It also reviews a stepwise monitoring approach, focusing on tolerability at three months and efficacy assessments at six and twelve months, with an emphasis on histologic and non-invasive test improvements.
Watch Now
Defining, Diagnosing, & Treating MASH
At Jan 24, 2025
Join Jordan Mayberry, PA-C, for an insightful video from the MASH Boot Camp at the 2024 GHAPP National Conference. Jordan covers the latest advancements in diagnosing metabolic-associated steatohepatitis (MASH). She provides a comprehensive overview of the evolution of MASH terminology, the diagnostic criteria, and the critical role of patient history in identifying steatosis. Discover how metabolic risk factors, genetic predispositions, and alcohol consumption influence disease progression. Jordan also explores the importance of non-invasive diagnostic tools, when to consider liver biopsies, and how to differentiate MASH from other liver conditions. Perfect for healthcare professionals seeking to refine their approach to liver disease management.
Watch Now
Types of Diet for the Treatment of MASLD
At Jan 23, 2025
This video explores comprehensive strategies for managing metabolic-associated steatohepatitis (MASH), focusing on fibrosis risk stratification, lifestyle modifications, and pharmacologic interventions. Learn about dietary recommendations like the Mediterranean diet, exercise guidelines emphasizing resistance training, and the role of intermittent fasting and processed food avoidance. The video also highlights weight loss targets, diabetes management, and emerging therapies such as GLP-1 receptor agonists and bariatric surgery, all aimed at improving liver health and patient outcomes.
Watch Now
Third Step of Life Style Management
At Jan 23, 2025
This video provides a comprehensive overview of emerging pharmacologic treatments for metabolic-associated steatohepatitis (MASH) and their tailored applications based on patient profiles. Topics include FDA-approved therapies, drugs in advanced clinical trials (such as semaglutide and lanifibranor), and the potential for combination treatments targeting both steatohepatitis and fibrosis. The speaker emphasizes the importance of patient-specific approaches considering metabolic profiles, obesity, and diabetes status, alongside lifestyle interventions. Additionally, the video discusses the evolving interdisciplinary care model and highlights the exciting progress in non-invasive testing and treatment advancements for F2-F3 fibrosis.
Watch Now
Management of Life Style Modification
At Jan 23, 2025
This video focuses on the comprehensive management of patients with metabolic-associated steatohepatitis (MASH), emphasizing lifestyle modifications, dietary adjustments, and exercise strategies. Key topics include the importance of addressing risk factors like diet, exercise habits, and alcohol intake, as well as referrals to medically supervised weight loss clinics or bariatric surgery for advanced cases. The speaker highlights the benefits of the Mediterranean diet, intermittent fasting, and avoiding ultra-processed foods while discussing the role of resistance training to combat sarcopenia and maintain muscle mass. Practical advice and tailored recommendations ensure a holistic approach to managing MASH and improving patient outcomes.
Watch Now
Updates On Approved Treatments for MASH
At Jan 24, 2025
Join Robin Soto, NP, for an engaging session at the MASH Boot Camp during the 2024 GHAPP National Conference as she provides updates on improved treatments for metabolic-associated steatohepatitis (MASH). Robin dives into the mechanisms of action, key clinical data, and prescribing guidelines for current therapies, including groundbreaking updates from the MAESTRO-NASH study. She also explores the game-changing potential of FDA-approved therapies like Resmetirom, offering insights into its efficacy, safety, and impact on patients with at-risk fibrosis.
Watch Now